Addressing shareholder concerns

Giv­en yes­ter­day’s news about a gov­ern­ment inves­ti­ga­tion that inter­viewed sev­er­al Lazar Phar­ma­ceu­ti­cal employ­ees, com­bined with the recent volatil­i­ty in the stock mar­ket, I would like to address the con­cerns I’ve been hear­ing from our shareholders.

First off, the facts about the gov­ern­ment inves­ti­ga­tion that was revealed on CNBC, CNN and oth­er tele­vi­sion news chan­nels yes­ter­day. This is NOT an inves­ti­ga­tion of Lazar Phar­ma­ceu­ti­cals or any of our cor­po­rate activ­i­ties. Rather, the Naval Crim­i­nal Inves­tiga­tive Ser­vice (NCIS) has ques­tioned sev­er­al Lazar employ­ees in con­nec­tion with the dis­ap­pear­ance of a US Navy mid­ship­man who was enrolled in one of Lazar’s clin­i­cal tri­als.  Read more